Literature DB >> 7539007

Carboxyl-terminal prodomain-deleted human leukocyte elastase and cathepsin G are efficiently targeted to granules and enzymatically activated in the rat basophilic/mast cell line RBL.

U Gullberg1, A Lindmark, G Lindgren, A M Persson, E Nilsson, I Olsson.   

Abstract

The hematopoietic neutral serine proteases leukocyte elastase and cathepsin G are synthesized as inactive precursors, but become activated by removal of an amino-terminal dipeptide and are stored in granules. Moreover, the pro forms of elastase and cathepsin G show carboxyl-terminal prodomains of 20 and 11 amino acids, respectively, which are not present in the mature enzymes. To investigate mechanisms of processing, activation, and granular targeting, we have utilized transgenic expression of myeloid serine proteases in the rat basophilic/mast cell line RBL-1 (Gullberg, U., Lindmark, A., Nilsson, E., Persson, A.-M., and Olsson, I. (1994) J. Biol. Chem. 269, 25219-25225). Leukocyte elastase was stably expressed in RBL-1 cells, and the translation products were characterized by biosynthetic labeling followed by immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and fluorography. Processing of a main pro form of 34 kDa into mature 31- and 29-kDa forms was demonstrated. Translocation of mature forms to granule-containing fractions was shown by subcellular fractionation experiments. The processed forms were enzymatically active, judging by the occurrence of amino-terminal processing demonstrated by radiosequence analysis, the acquisition of affinity for the protease inhibitor aprotinin, and the appearance of elastase activity in transfected RBL cells. To investigate the function of the carboxyl-terminal prodomains, deletion mutants of leukocyte elastase and cathepsin G lacking the carboxyl-terminal extension were constructed and transfected into RBL cells. Our results show that as full-length proteins, the deletion mutants were converted to active enzymes and transferred to granules with kinetics similar to that of wild-type enzymes. We conclude that human leukocyte elastase and cathepsin G are converted into enzymatically active forms when expressed in RBL cells and targeted for storage in granules; the carboxyl-terminal prodomains are necessary neither for enzymatic activation nor for targeting to granules in RBL cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539007     DOI: 10.1074/jbc.270.21.12912

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions.

Authors:  Ian Loke; Ole Østergaard; Niels H H Heegaard; Nicolle H Packer; Morten Thaysen-Andersen
Journal:  Mol Cell Proteomics       Date:  2017-06-19       Impact factor: 5.911

3.  Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane.

Authors:  Suparna Nanua; Mark Murakami; Jun Xia; David S Grenda; Jill Woloszynek; Marie Strand; Daniel C Link
Journal:  Blood       Date:  2011-02-01       Impact factor: 22.113

4.  Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages.

Authors:  Marilia S Faria; Flavia C G Reis; Ricardo L Azevedo-Pereira; Lesley S Morrison; Jeremy C Mottram; Ana Paula C A Lima
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

Review 5.  Neutrophil elastase in cyclic and severe congenital neutropenia.

Authors:  Marshall S Horwitz; Zhijun Duan; Brice Korkmaz; Hu-Hui Lee; Matthew E Mealiffe; Stephen J Salipante
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

6.  Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells.

Authors:  Ramesh C Nayak; Lisa R Trump; Bruce J Aronow; Kasiani Myers; Parinda Mehta; Theodosia Kalfa; Ashley M Wellendorf; C Alexander Valencia; Patrick J Paddison; Marshall S Horwitz; H Leighton Grimes; Carolyn Lutzko; Jose A Cancelas
Journal:  J Clin Invest       Date:  2015-07-20       Impact factor: 14.808

7.  Contributions to neutropenia from PFAAP5 (N4BP2L2), a novel protein mediating transcriptional repressor cooperation between Gfi1 and neutrophil elastase.

Authors:  Stephen J Salipante; Meghan E B Rojas; Brice Korkmaz; Zhijun Duan; Jeremy Wechsler; Kathleen F Benson; Richard E Person; H Leighton Grimes; Marshall S Horwitz
Journal:  Mol Cell Biol       Date:  2009-06-08       Impact factor: 4.272

8.  Neutropenia-associated ELANE mutations disrupting translation initiation produce novel neutrophil elastase isoforms.

Authors:  Timothy Tidwell; Jeremy Wechsler; Ramesh C Nayak; Lisa Trump; Stephen J Salipante; Jerry C Cheng; Jean Donadieu; Taly Glaubach; Seth J Corey; H Leighton Grimes; Carolyn Lutzko; Jose A Cancelas; Marshall S Horwitz
Journal:  Blood       Date:  2013-11-01       Impact factor: 22.113

9.  Cathepsin G induces cell aggregation of human breast cancer MCF-7 cells via a 2-step mechanism: catalytic site-independent binding to the cell surface and enzymatic activity-dependent induction of the cell aggregation.

Authors:  Riyo Morimoto-Kamata; Sei-ichiro Mizoguchi; Takeo Ichisugi; Satoru Yui
Journal:  Mediators Inflamm       Date:  2012-07-08       Impact factor: 4.711

10.  α1Proteinase inhibitor regulates CD4+ lymphocyte levels and is rate limiting in HIV-1 disease.

Authors:  Cynthia L Bristow; Mariya A Babayeva; Michelle LaBrunda; Michael P Mullen; Ronald Winston
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.